Hipertensión esencial

National Heart, Lung, and Blood Institute. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Aug 2004 [internet publication].Texto completo external link opens in a new window

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104.Texto completo external link opens in a new windowResumen external link opens in a new window

James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.Texto completo external link opens in a new windowResumen external link opens in a new window

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.Texto completo external link opens in a new windowResumen external link opens in a new window

Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16.Texto completo external link opens in a new windowResumen external link opens in a new window

Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020 May;36(5):596-624.Texto completo external link opens in a new windowResumen external link opens in a new window

Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015 Nov 21;386(10008):2059-68.Texto completo external link opens in a new windowResumen external link opens in a new window

1. National Heart, Lung, and Blood Institute. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Aug 2004 [internet publication].Texto completo external link opens in a new window

2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104.Texto completo external link opens in a new windowResumen external link opens in a new window

3. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.Texto completo external link opens in a new windowResumen external link opens in a new window

4. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998 Jun 13;351(9118):1755-62.Resumen external link opens in a new window

5. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.Texto completo external link opens in a new windowResumen external link opens in a new window

6. The SPRINT Study Research Group. Systolic Blood Pressure Intervention Trial. 2016 [internet publication].Texto completo external link opens in a new window

7. Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16.Texto completo external link opens in a new windowResumen external link opens in a new window

8. World Health Organization. Hypertension. Sep 2019 [internet publication].Texto completo external link opens in a new window

9. Singh RB, Suh IL, Singh VP, et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens. 2000 Oct-Nov;14(10-11):749-63.Texto completo external link opens in a new windowResumen external link opens in a new window

10. Yusuf S, Reddy S, Ôunpuu S, et al. Global burden of cardiovascular diseases. Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001 Dec 4;104(22):2746-53.Texto completo external link opens in a new windowResumen external link opens in a new window

11. Khor GL. Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr. 2001;10(2):76-80.Resumen external link opens in a new window

12. Public Health England. Health matters: combating high blood pressure. Jan 2017 [internet publication].Texto completo external link opens in a new window

13. Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. J Am Coll Cardiol. 2018 Jan 16;71(2):109-18.Texto completo external link opens in a new windowResumen external link opens in a new window

14. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics - 2020 update: a report from the American Heart Association. Circulation. 2020 Mar 3;141(9):e139-596.Texto completo external link opens in a new windowResumen external link opens in a new window

15. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002 Feb 27;287(8):1003-10.Texto completo external link opens in a new windowResumen external link opens in a new window

16. Coggon DI, Martyn CN. Time and chance: the stochastic nature of disease causation. Lancet. 2005 Apr 16-22;365(9468):1434-7.Resumen external link opens in a new window

17. Saad MF, Rewers M, Selby J, et al. Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis Study. Hypertension. 2004 Jun;43(6):1324-31.Texto completo external link opens in a new windowResumen external link opens in a new window

18. Andersson OK, Beckman-Suurkula M, Sannerstedt R, et al. Does hyperkinetic circulation constitute a pre-hypertensive state? J Intern Med. 1989 Dec;226(6):401-8.Resumen external link opens in a new window

19. Morimoto A, Uzu T, Fujii T, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997 Dec 13;350(9093):1734-7.Resumen external link opens in a new window

20. Weinberger MH. More on the sodium saga. Hypertension. 2004 Nov;44(5):609-11.Texto completo external link opens in a new windowResumen external link opens in a new window

21. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure: less of one, more the other? Am J Hypertens. 1988 Oct;1(4 Pt 1):335-47.Resumen external link opens in a new window

22. Blaustein MP. Endogenous ouabain: role in the pathogenesis of hypertension. Kidney Int. 1996 Jun;49(6):1748-53.Texto completo external link opens in a new windowResumen external link opens in a new window

23. Cowley AW Jr, Roman RJ. The role of the kidney in hypertension. JAMA. 1996 May 22-29;275(20):1581-9.Resumen external link opens in a new window

24. Laragh JH. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001 Jan;14(1):84-9.Resumen external link opens in a new window

25. Fuchs S, Frenzel K, Xiao HD, et al. Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme. Curr Hypertens Rep. 2004 Apr;6(2):124-8.Resumen external link opens in a new window

26. Grassi G, Mancia G. Neurogenic hypertension: is the enigma of its origin near its solution? Hypertension. 2004 Feb;43(2):154-5.Texto completo external link opens in a new windowResumen external link opens in a new window

27. Schriffin EL. Remodeling of resistance arteries in essential hypertension and the effects of antihypertensive treatment. Am J Hypertens. 2004 Dec;17(12 Pt 1):1192-200.Texto completo external link opens in a new windowResumen external link opens in a new window

28. Rossi R, Chiurlia E, Nuzzo A, et al. Flow-mediated vasodilation and the risk of developing hypertension in healthy post-menopausal women. J Am Coll Cardiol. 2004 Oct 19;44(8):1636-40.Texto completo external link opens in a new windowResumen external link opens in a new window

29. Russo C, Oliveri O, Girelli D, et al. Increased membrane ratios of metabolite to precursor fatty acid in essential hypertension. Hypertension. 1997 Apr;29(4):1058-63.Texto completo external link opens in a new windowResumen external link opens in a new window

30. Sharma AM, Engeli S, Pischon T. New developments in mechanisms of obesity-induced hypertension: role of adipose tissue. Curr Hypertens Rep. 2001 Apr;3(2):152-6.Resumen external link opens in a new window

31. Faxon DP, Creager MA, Smith SC Jr, et al. Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2004 Jun 1;109(21):2595-604.Texto completo external link opens in a new windowResumen external link opens in a new window

32. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001 Nov 1;345(18):1291-7.Texto completo external link opens in a new windowResumen external link opens in a new window

33. Huang Z, Willet WC, Manson JE, et al. Bodyweight, weight change and risk of hypertension in women. Ann Intern Med. 1998 Jan 15;128(2):81-8.Resumen external link opens in a new window

34. Kannel WB, Garrison RJ, Dannenberg AL. Secular blood pressure trends in normotensive patients. Am Heart J. 1993 Apr;125(4):1154-8.Resumen external link opens in a new window

35. Jayedi A, Rashidy-Pour A, Khorshidi M, et al. Body mass index, abdominal adiposity, weight gain and risk of developing hypertension: a systematic review and dose-response meta-analysis of more than 2.3 million participants. Obes Rev. 2018 Jan 15;19(5):654-67.Resumen external link opens in a new window

36. Heneghan HM, Meron-Eldar S, Brethauer SA, et al. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol. 2011 Nov 15;108(10):1499-507.Resumen external link opens in a new window

37. Sarkhosh K, Birch DW, Shi X, et al. The impact of sleeve gastrectomy on hypertension: a systematic review. Obes Surg. 2012 May;22(5):832-7.Resumen external link opens in a new window

38. Huang L, Trieu K, Yoshimura S, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ. 2020 Feb 24;368:m315.Texto completo external link opens in a new windowResumen external link opens in a new window

39. Blair SN, Goodyear NN, Gibbons LW, et al. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA. 1984 Jul 27;252(4):487-90.Resumen external link opens in a new window

40. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001 Jan 4;344(1):3-10.Texto completo external link opens in a new windowResumen external link opens in a new window

41. Thadhani R, Camargo CA, Stampfer MJ, et al. Prospective study of moderate alcohol consumption and risk of hypertension in young women. Arch Intern Med. 2002 Mar 11;162(5):569-74.Texto completo external link opens in a new windowResumen external link opens in a new window

42. Tasnim S, Tang C, Musini VM, et al. Effect of alcohol on blood pressure. Cochrane Database Syst Rev. 2020 Jul 1;(7):CD012787.Texto completo external link opens in a new windowResumen external link opens in a new window

43. Ding J, Visser M, Kritschevsky SB, et al. The association of regional fat depots with hypertension in older persons of white and African American ethnicity. Am J Hypertens. 2004 Oct;17(10):971-6.Texto completo external link opens in a new windowResumen external link opens in a new window

44. Bjornholt JV, Erikssen G, Kjeldsen SE, et al. Fasting blood glucose is independently associated with resting and exercising blood pressures and development of elevated blood pressures. J Hypertens. 2003 Jul;21(7):1383-9.Resumen external link opens in a new window

45. Xia W, Huang Y, Peng B, et al. Relationship between obstructive sleep apnoea syndrome and essential hypertension: a dose-response meta-analysis. Sleep Med. 2018 Jul;47:11-18.Resumen external link opens in a new window

46. Hou H, Zhao Y, Yu W, et al. Association of obstructive sleep apnea with hypertension: a systematic review and meta-analysis. J Glob Health. 2018 Jun;8(1):010405.Texto completo external link opens in a new windowResumen external link opens in a new window

47. United States Department of Agriculture, Center for Nutrition Policy and Promotion. Dietary guidelines for Americans 2015-2020. Dec 2015 [internet publication].Texto completo external link opens in a new window

48. He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD004937.Texto completo external link opens in a new windowResumen external link opens in a new window

49. Stergiou GS, Bliziotis IA. Home blood pressure monitoring in the diagnosis and treatment of hypertension: a systematic review. Am J Hypertens. 2011 Feb;24(2):123-34.Resumen external link opens in a new window

50. US Preventive Services Task Force. High blood pressure in adults: screening. Oct 2015 [internet publication].Texto completo external link opens in a new window

51. Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension. 2019 May;73(5):e35-66.Texto completo external link opens in a new windowResumen external link opens in a new window

52. Cloutier L, Daskalopoulou SS, Padwal RS, et al. A new algorithm for the diagnosis of hypertension in Canada. Can J Cardiol. 2015 May;31(5):620-30.Texto completo external link opens in a new windowResumen external link opens in a new window

53. Myers MG. A short history of automated office blood pressure - 15 years to SPRINT. J Clin Hypertens (Greenwich). 2016 Aug;18(8):721-4.Texto completo external link opens in a new windowResumen external link opens in a new window

54. Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med. 2019 Mar 1;179(3):351-62.Texto completo external link opens in a new windowResumen external link opens in a new window

55. Cuspidi C. Cardio-renal organ damage and cardiovascular outcomes in hypertension. J Hypertens. 2009 Apr;27(4):702-6.Resumen external link opens in a new window

56. Milani RV, Lavie CJ, Mehra MR, et al. Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol. 2006 Apr 1;97(7):959-63.Resumen external link opens in a new window

57. Yasuno S, Ueshima K, Oba K, et al. Clinical significance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan trial. J Hypertens. 2009 Aug;27(8):1705-12.Resumen external link opens in a new window

58. Zanchetti A, Hennig M, Hollweck R, et al. Baseline values but not treatment induced changes in carotid intima media thickness predict incident cardiovascular events in treated hypertensives: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009 Sep 22;120(12):1084-90.Resumen external link opens in a new window

59. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916.Texto completo external link opens in a new windowResumen external link opens in a new window

60. Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020 May;36(5):596-624.Texto completo external link opens in a new windowResumen external link opens in a new window

61. Dobbin SJH, Cameron AC, Petrie MC, et al. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart. 2018 Dec;104(24):1995-2002.Resumen external link opens in a new window

62. Piper MA, Evans CV, Burda BU, et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015 Feb 3;162(3):192-204.Texto completo external link opens in a new windowResumen external link opens in a new window

63. Musini VM, Tejani AM, Bassett K, et al. Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Database Syst Rev. 2019 Jun 5;(6):CD000028.Texto completo external link opens in a new windowResumen external link opens in a new window

64. Wright Jr JT, Fine LJ, Lackland DT, et al. Evidence supporting a systolic blood pressure goal of less than 150 mmHg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014 Apr 1;160(7):499-503.Texto completo external link opens in a new windowResumen external link opens in a new window

65. Qaseem A, Wilt TJ, Rich R, et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017 Mar 21;166(6):430-7.Texto completo external link opens in a new windowResumen external link opens in a new window

66. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016 Jan 30;387(10017):435-43.Resumen external link opens in a new window

67. Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16.Texto completo external link opens in a new windowResumen external link opens in a new window

68. Vaduganathan M, Claggett BL, Juraschek SP, et al. Assessment of long-term benefit of intensive blood pressure control on residual life span: secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol. 2020 May 1;5(5):576-81.Resumen external link opens in a new window

69. Lonn EM, Bosch J, López-Jaramillo P, et al; HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016 May 26;374(21):2009-20.Resumen external link opens in a new window

70. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008 May 1;358(18):1887-98.Texto completo external link opens in a new windowResumen external link opens in a new window

71. Williamson JD, Supiano MA, Applegate WB, et al; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016 Jun 28;315(24):2673-82.Texto completo external link opens in a new windowResumen external link opens in a new window

72. Benetos A, Rossignol P, Cherubini A, et al. Polypharmacy in the aging patient: management of hypertension in octogenarians. JAMA. 2015 Jul 14;314(2):170-80.Resumen external link opens in a new window

73. Cushman WC, Evans GW, Byington RP, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85.Texto completo external link opens in a new windowResumen external link opens in a new window

74. American Diabetes Association. Standards of medical care in diabetes - 2020. Diabetes Care. 2020 Jan;43(Suppl 1):S1-212.Texto completo external link opens in a new window

75. Geleijinse JM, Kork FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a meta-regression analysis of randomized trials. J Hum Hypertens. 2003 Jul;17(7):471-80.Resumen external link opens in a new window

76. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002 Apr 2;136(7):493-503.Resumen external link opens in a new window

77. Hartley TR, Lovallo WR, Whisett TL, et al. Cardiovascular effects of caffeine in men and women. Am J Cardiol. 2004 Apr 15;93(8):1022-6.Resumen external link opens in a new window

78. Gradman AH, Basile JN, Carter BL, et al; American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens. 2010 Jan-Feb;4(1):42-50.Resumen external link opens in a new window

79. Savage RD, Visentin JD, Bronskill SE, et al. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern Med. 2020 May 1;180(5):643-51.Resumen external link opens in a new window

80. Salam A, Kanukula R, Atkins E, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019 Sep;37(9):1768-74.Resumen external link opens in a new window

81. Bangalore S, Fakheri R, Toklu B, et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016 Feb 11;352:i438.Texto completo external link opens in a new windowResumen external link opens in a new window

82. Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019 Nov 16;394(10211):1816-26.Resumen external link opens in a new window

83. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018 Apr 18;(4):CD001841.Texto completo external link opens in a new windowResumen external link opens in a new window

84. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 Dec 18;288(23):2981-97.Texto completo external link opens in a new windowResumen external link opens in a new window

85. Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 Sep;48(3):374-84.Texto completo external link opens in a new windowResumen external link opens in a new window

86. Thurman JM, Schrier RW. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med. 2003 May;114(7):588-98.Resumen external link opens in a new window

87. Beta Blocker Heart Attack Trial. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982 Mar 26;247(12):1707-14.Resumen external link opens in a new window

88. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992 Sep 3;327(10):669-77.Resumen external link opens in a new window

89. Tepper D. Frontiers in congestive heart failure: effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Congest Heart Fail. 1999 Jul-Aug;5(4):184-5.Resumen external link opens in a new window

90. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651-8.Texto completo external link opens in a new windowResumen external link opens in a new window

91. Lindenauer PK, Fitzgerald J, Hoople N, et al. The potential preventability of postoperative myocardial infarction: underuse of perioperative beta-adrenergic blockade. Arch Intern Med. 2004 Apr 12;164(7):762-6.Texto completo external link opens in a new windowResumen external link opens in a new window

92. Yusuf S, Sleight P, Pogue J, et al; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53.Texto completo external link opens in a new windowResumen external link opens in a new window

93. The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003 Sep 6;362(9386):782-8.Resumen external link opens in a new window

94. Braunwald E, Domanski MJ, Fowler SE, et al; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004 Nov 11;351(20):2058-68.Texto completo external link opens in a new windowResumen external link opens in a new window

95. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 4;316(23):1429-35.Resumen external link opens in a new window

96. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002 Sep 7;360(9335):752-60.Resumen external link opens in a new window

97. McMurray J, Östergren J, Pfeffer M, et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2003 Jun;5(3):261-70.Texto completo external link opens in a new windowResumen external link opens in a new window

98. Black HR, Sollins JS, Garofalo JL. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens. 2000 May;13(5 Pt 1):468-74.Resumen external link opens in a new window

99. Velasquez EJ, Pfeffer MA, McMurray JV, et al; VALIANT Investigators. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail. 2003 Aug;5(4):537-44.Texto completo external link opens in a new windowResumen external link opens in a new window

100. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17.Texto completo external link opens in a new windowResumen external link opens in a new window

101. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986 Jun 12;314(24):1547-52.Resumen external link opens in a new window

102. Taylor AL, Ziesche S, Yancy C, et al; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004 Nov 11;351(20):2049-57.Texto completo external link opens in a new windowResumen external link opens in a new window

103. Qiao Y, Shin JI, Chen TK, et al. Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med. 2020 May 1;180(5):718-26.Resumen external link opens in a new window

104. Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004 Jun;65(6):1991-2002.Texto completo external link opens in a new windowResumen external link opens in a new window

105. Navaneethan SD, Nigwekar SU, Sehgal AR, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009 Mar;4(3):542-51.Texto completo external link opens in a new windowResumen external link opens in a new window

106. Alexandrou ME, Papagianni A, Tsapas A, et al. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019 Dec;37(12):2307-24.Resumen external link opens in a new window

107. Yusuf S, Diener HC, Sacco RL, et al; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008 Sep 18;359(12):1225-37.Texto completo external link opens in a new windowResumen external link opens in a new window

108. Yusuf S, Teo K, Anderson C, et al; Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008 Sep 27;372(9644):1174-83.Resumen external link opens in a new window

109. Tveit A, Grundvold I, Olufsen M, et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007 Aug 9;120(1):85-91.Resumen external link opens in a new window

110. Disertori M, Latini R, Barlera S, et al; GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009 Apr 16;360(16):1606-17. [Erratum in: N Engl J Med. 2009 May 28;360(22):2379.]Texto completo external link opens in a new windowResumen external link opens in a new window

111. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76.Texto completo external link opens in a new windowResumen external link opens in a new window

112. Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004 Sep;17(9):817-22.Texto completo external link opens in a new windowResumen external link opens in a new window

113. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized control trial. Lancet. 2004 Sep 4-10;364(9437):849-57.Resumen external link opens in a new window

114. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018 Nov;72(5):e53-90.Texto completo external link opens in a new windowResumen external link opens in a new window

115. Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015 Nov 21;386(10008):2059-68.Texto completo external link opens in a new windowResumen external link opens in a new window

116. Charpentier MM, Bundeff A. Treating hypertension in the very elderly. Ann Pharmacother. 2011 Sep;45(9):1138-43.Resumen external link opens in a new window

117. Schall P, Wehling M. Treatment of arterial hypertension in the very elderly: a meta-analysis of clinical trials. Arzneimittelforschung. 2011;61(4):221-8.Resumen external link opens in a new window

118. Williamson JD, Pajewski NM, Auchus AP, et al; SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019 Feb 12;321(6):553-61.Texto completo external link opens in a new windowResumen external link opens in a new window

119. Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013 Aug 21;310(7):699-705.Texto completo external link opens in a new windowResumen external link opens in a new window

120. Sim JJ, Handler J, Jacobsen SJ, et al. Systematic implementation strategies to improve hypertension: the Kaiser Permanente southern California experience. Can J Cardiol. 2014 May;30(5):544-52.Resumen external link opens in a new window

121. Shaw KM, Handler J, Wall HK, et al. Improving blood pressure control in a large multiethnic California population through changes in health care delivery 2004-2012. Prev Chronic Dis. 2014 Oct 30;11:E191.Texto completo external link opens in a new windowResumen external link opens in a new window

122. Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014 Jul;47(1):86-99.Resumen external link opens in a new window

123. Carter BL, Bosworth HB, Green BB. The hypertension team: the role of the pharmacist, nurse, and teamwork in hypertension therapy. J Clin Hypertens (Greenwich). 2012 Jan;14(1):51-65.Texto completo external link opens in a new windowResumen external link opens in a new window

124. Cicolini G, Simonetti V, Comparcini D, et al. Efficacy of a nurse-led email reminder program for cardiovascular prevention risk reduction in hypertensive patients: a randomized controlled trial. Int J Nurs Stud. 2014 Jun;51(6):833-43.Resumen external link opens in a new window

125. McManus RJ, Mant J, Franssen M, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet. 2018 Mar 10;391(10124):949-59.Texto completo external link opens in a new windowResumen external link opens in a new window

126. Ayanian JZ, Landon BE, Newhouse JP, et al. Racial and ethnic disparities among enrollees in Medicare Advantage plans. N Engl J Med. 2014 Dec 11;371(24):2288-97.Texto completo external link opens in a new windowResumen external link opens in a new window

127. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003.Resumen external link opens in a new window

128. Ong HT. Beta blockers in hypertension and cardiovascular disease. BMJ. 2007 May 5;334(7600):946-9.Texto completo external link opens in a new windowResumen external link opens in a new window

129. Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2019 Oct 22 [Epub ahead of print].Texto completo external link opens in a new windowResumen external link opens in a new window

130. Bhatt DL, Kandzari DE, O'Neill WW, et al; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10;370(15):1393-401.Texto completo external link opens in a new windowResumen external link opens in a new window

131. Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018 Jun 9;391(10137):2346-55.Resumen external link opens in a new window

132. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018 Jun 0;391(10137):2335-45.Resumen external link opens in a new window

133. Oliveras A, Armario P, Clarà A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens. 2016 Sep;34(9):1863-71.Texto completo external link opens in a new windowResumen external link opens in a new window

134. Rosa J, Widimský P, Waldauf P, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension. 2015 Feb;67(2):397-403.Texto completo external link opens in a new windowResumen external link opens in a new window

135. Fadl Elmula FEM, Feng YM, Jacobs L, et al. Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Press. 2017 Aug;26(4):195-203.Texto completo external link opens in a new windowResumen external link opens in a new window

136. Azizi M, Schmieder RE, Mahfoud F, et al; RADIANCE-HTN Investigators. Six-month results of treatment-blinded medication titration for hypertension control following randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO Trial. Circulation. 2019 May 28;139(22):2542-53.Texto completo external link opens in a new windowResumen external link opens in a new window

137. Böhm M, Kario K, Kandzari DE, et al; SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020 May 2;395(10234):1444-51.Resumen external link opens in a new window

138. Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010 Mar;55(3):619-26.Texto completo external link opens in a new windowResumen external link opens in a new window

139. Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006 Dec;44(6):1213-8.Resumen external link opens in a new window

140. Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010 Oct 5;56(15):1254-8.Texto completo external link opens in a new windowResumen external link opens in a new window

141. Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012 Mar-Apr;6(2):152-8.Resumen external link opens in a new window

142. Dong JY, Qin LQ, Zhang Z, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J. 2011 Dec;162(6):959-65.Resumen external link opens in a new window

143. Juraschek SP, Guallar E, Appel LJ, et al. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012 May;95(5):1079-88.Texto completo external link opens in a new windowResumen external link opens in a new window

144. Tamez H, Thadhani RI. Vitamin D and hypertension: an update and review. Curr Opin Nephrol Hypertens. 2012 Sep;21(5):492-9.Resumen external link opens in a new window

145. Tamez H, Kalim S, Thadhani RI. Does vitamin D modulate blood pressure? Curr Opin Nephrol Hypertens. 2013 Mar;22(2):204-9.Texto completo external link opens in a new windowResumen external link opens in a new window

146. Beveridge LA, Struthers AD, Khan F, et al; D-PRESSURE Collaboration. Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med. 2015 May;175(5):745-54.Texto completo external link opens in a new windowResumen external link opens in a new window

147. Cormick G, Ciapponi A, Caffereta ML, et al. Calcium supplementation for prevention of primary hypertension. Cochrane Database Syst Rev. 2015 Jun 30;(6):CD010037.Texto completo external link opens in a new windowResumen external link opens in a new window

148. Tikkanen I, Narko K, Zeller C, et al; EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015 Mar;38(3):420-8.Texto completo external link opens in a new windowResumen external link opens in a new window

149. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.Texto completo external link opens in a new windowResumen external link opens in a new window

150. Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014 Dec;16(12):875-82.Texto completo external link opens in a new windowResumen external link opens in a new window

151. Williams B, MacDonald TM, Morant SV, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018 Jun;6(6):464-75.Texto completo external link opens in a new windowResumen external link opens in a new window

152. Ferdinand KC, Balavoine F, Besse B, et al. Efficacy and safety of firibastat, a first-in-class brain aminopeptidase A inhibitor, in hypertensive overweight patients of multiple ethnic origins. Circulation. 2019 Jul 9;140(2):138-46.Texto completo external link opens in a new windowResumen external link opens in a new window

153. Flint AC, Conell C, Ren X, et al. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med. 2019 Jul 18;381(3):243-51.Texto completo external link opens in a new windowResumen external link opens in a new window

154. Cohen JB, Lotito MJ, Trivedi UK, et al. Cardiovascular events and mortality in white coat hypertension: a systematic review and meta-analysis. Ann Intern Med. 2019 Jun 18;170(12):853-62.Resumen external link opens in a new window

155. Anstey DE, Pugliese D, Abdalla M, et al. An update on masked hypertension. Curr Hypertens Rep. 2017 Oct 25;19(12):94.Texto completo external link opens in a new windowResumen external link opens in a new window

156. Nuyujukian DS, Koska J, Bahn G, et al; VADT Investigators. Blood pressure variability and risk of heart failure in ACCORD and the VADT. Diabetes Care. 2020 Jul;43(7):1471-8.Resumen external link opens in a new window

157. Hermida RC, Ayala DE, Mojón A, et al. Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am J Hypertens. 2012 Mar;25(3):325-34.Resumen external link opens in a new window

158. Hermida RC, Ayala DE, Mojón A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011 Dec;22(12):2313-21.Texto completo external link opens in a new windowResumen external link opens in a new window

159. Hermida RC, Ayala DE, Mojón A, et al. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol. 2011 Sep 6;58(11):1165-73.Resumen external link opens in a new window

160. Hermida RC, Ayala DE, Mojón A, et al. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol Int. 2011 Aug;28(7):601-10.Resumen external link opens in a new window

161. Hermida RC, Ayala DE, Mojón A, et al. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011 Jun;34(6):1270-6.Texto completo external link opens in a new windowResumen external link opens in a new window

162. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13.Resumen external link opens in a new window

163. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001 Sep 29;358(9287):1033-41.Resumen external link opens in a new window

164. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996 May 22-29;275(20):1557-62.Resumen external link opens in a new window

165. Hagan PG, Nienaber CA, Isselbacher EM, et al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA. 2000 Feb 16;283(7):897-903.Texto completo external link opens in a new windowResumen external link opens in a new window

166. Prisant LM, Nalamolu VR. Aortic dissection. J Clin Hypertens (Greenwich). 2005 Jun;7(6):367-71.Texto completo external link opens in a new windowResumen external link opens in a new window

167. Schmieder RE, Messerli FH. Hypertension and the heart. J Hum Hypertens. 2000 Oct-Nov;14(10-11):597-604.Resumen external link opens in a new window

168. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001 Mar;141(3):334-41.Resumen external link opens in a new window

169. Devereux RB, Roman MJ, Ganau A, et al. Cardiac and arterial hypertrophy and atherosclerosis in hypertension. Hypertension. 1994 Jun;23(6 Pt 1):802-9.Resumen external link opens in a new window

170. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004 Nov;44(5):595-601.Texto completo external link opens in a new windowResumen external link opens in a new window

171. Marcantoni C, Ma LJ, Federspiel C, et al. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int. 2002 Jul;62(1):172-80.Texto completo external link opens in a new windowResumen external link opens in a new window

172. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001 Aug 16;345(7):479-86.Texto completo external link opens in a new windowResumen external link opens in a new window

173. Poulsen PL, Ebbehoj E, Hansen KW, et al. Effects of smoking on 24-h ambulatory blood pressure and autonomic function in normoalbuminuric insulin-dependent diabetes mellitus patients. Am J Hypertens. 1998 Sep;11(9):1093-9.Resumen external link opens in a new window

174. Stamler J, Caggiula AW, Gandits GA. Relation of body mass and alcohol, nutrient, fiber, and caffeine intakes to blood pressure in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. Am J Clin Nutr. 1997 Jan;65(1 Suppl):338S-65S.Resumen external link opens in a new window